Company Overview and News
Last week, Atlanta, GA-based airline behemoth Delta Air Lines, Inc. (DAL - Free Report) raised its projection for second-quarter fuel costs per gallon owing to the upsurge in oil prices. Moreover, the carrier trimmed its earnings per share view due to the same reason.
SKYW HA UAL ALK DAL
U.S. stock markets continue their winning run as all three major indexes ended higher on Monday. However, the gains were moderate since the investors are anticipating the outcome of the much anticipated meeting between President Donald Trump and his North Korean counterpart Kim Jong Un. Additionally, markets will closely watch this week’s meetings of three major central banks: the U.S. Federal Reserve, the European Central Bank and the Bank of Japan.
HA FDX UNH
Hawaiian Holdings, Inc.’s (HA - Free Report) wholly owned subsidiary, Hawaiian Airlines, reported traffic figures for May. Traffic (measured in Revenue Passenger Miles or RPMs) increased 5.6% to around 1.45 billion. Available Seat Miles (ASMs) also climbed 6.5% to 1.68 billion in the month. Load factor (percentage of seats filled by passengers) contracted 80 basis points (bps) to 85.9% as traffic growth was outpaced by capacity expansion.
GATX EXPD SKYW HA TRI GMTA GMT
Per Reuters, Hawaiian Holdings, Inc. (HA - Free Report) subsidiary Hawaiian Airlines’ CEO Peter Ingram stated that the carrier has suffered a slight decline in bookings following an eruption at Hawaii’s Kilauea volcano. The company’s CEO further commented on the sidelines of an airline industry conference that the flights from Honolulu to Hilo and Kona faced the largest impact as these airports are situated on the island of the spewing volcano.
GATX EXPD SKYW HA GMTA GMT
At its Annual General Meeting in Sydney, the International Air Transport Association (“IATA”) trimmed its forecast for airlines with respect to profitability for 2018. The research firm predicts that the global net profit for the industry to be $33.8 billion. This is much lower than the 2018 profitability forecast of $38.4 billion, which was unveiled by the organization in December 2017.
DB AAL HA RYAOF RYAAY UAL ALK DAL
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
C6L BOE AAL HA SINGY BA SINGF
Sydney/Mumbai: Boeing Co.’s efforts to undermine sales of Airbus SE’s newest widebody aircraft—the A330neo—have moved beyond US borders and into India, a market seen by the European planemaker as crucial to extending sales for the plane into Asia.
C6L BOE AAL HA SINGY BA SINGF
The order battle between Boeing (NYSE: BA) and Airbus (OTCPK:EADSF, OTCPK:EADSY) is one way for the companies to flex their muscles, next to marketing their respective products as the best solution with the highest fuel efficiency and passenger comfort. Even though the orders (in terms of value) are in no way a reflection of financial performance, it's important to have a look at the order inflow. That's because the order tallies give a nice impression of which manufacturer has the best mix of discount, comfort, slot availability and efficiency and it gives an idea of the overall health of the aircraft market and appetite for new aircraft.
Last week, Southwest Airlines Co. (LUV - Free Report) — one of leading players in the airline space — announced a 28% hike in its quarterly dividend payout to 16 cents per share (annualized 64 cents per share). The first installment of the raised dividend will be paid on Jun 27, 2018 to shareholders of record as of Jun 6.
SKYW HA UAL ALK DAL
Southwest Airlines Co (NYSE:LUV) has really struggled this year, with LUV stock down almost 20%. Ouch. That’s a pretty poor performance for a company that’s actually doing well. Given the huge decline so far this year, many investors are starting to wonder whether Southwest Airlines stock is a name to add to their portfolio.
BRK.A AAL BOE HA UAL BA DAL LUV
Load factor (percentage of seats filled by passengers) is an important indicator of profitability and efficiency for airline companies. Higher load factor implies the company is more profitable. This is because a high load factor means that the heavy fixed costs of airlines can be spread across more passengers. Load Factors Deteriorate in April This key metric declined in April for major US carriers, namely United Continental Holdings, Inc.
AAL HA JBLU SAVE UAL ALGT ALK DAL
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to HA / Hawaiian Holdings, Inc. on message board site Silicon Investor.
as of ET